Nestorone is a potent progesterone receptor agonist with no androgenic, estrogenic, or glucocorticoid-like activities.
Nestorone is a potent progesterone receptor agonist with no androgenic, estrogenic, or glucocorticoid-like activities. Nestorone has been used as a female contraceptive, and recent studies inidicate that it may be useful as a male contraceptive as well. It has also been shown to have neurogenic and neuroprotective activity.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Human reproduction update, 12(2), 169-178 (2005-11-18)
The progestins have different pharmacologic properties depending upon the parent molecule, usually testosterone or progesterone (P), from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In
We examined the clinical performance of contraceptive vaginal rings (rings) delivering Nestorone (NES) progestin and ethinyl estradiol (EE). Ring removal times were signaled by menstrual events. Bleeding patterns, adverse events, patterns of use and continuation rates were the principal parameters
A 2-year trial of a single Nestorone (NES) rod implant was conducted at three Latin American centers, each enrolling 100 women. We studied the safety, effectiveness and acceptability of this progestin-releasing contraceptive implant. Three pregnancies occurred, the last at 18
The Journal of clinical endocrinology and metabolism, 94(7), 2313-2320 (2009-04-16)
Testosterone (T) plus progestin combinations are the most promising hormonal male contraceptives. Nestorone (NES), a progestin without estrogenic or androgenic activity, when combined with T may be an excellent candidate for male contraception. Our objective was to determine the effect
The Journal of reproductive medicine, 48(8), 637-640 (2003-09-16)
To evaluate the prevalence of enlarged ovarian follicles among users of a 20 micrograms/d levonorgestrel-releasing intrauterine system (Mirena, Leiras Oy, Turku, Finland), of subdermal contraceptive implants releasing Nestorone (Population Council, New York, New York) and of the TCu 380A intrauterine
We offers many products related to Nuclear Receptors (Steroids) for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.